Abstract
Original language | English |
---|---|
Journal | Molecular Psychiatry |
Early online date | 2023 |
DOIs | |
Publication status | E-pub ahead of print - 2023 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
The functional connectome in obsessive-compulsive disorder : resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium. / ENIGMA-OCD Working Group.
In: Molecular Psychiatry, 2023.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - The functional connectome in obsessive-compulsive disorder
T2 - resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium
AU - Bruin, Willem B.
AU - Abe, Yoshinari
AU - Alonso, Pino
AU - Anticevic, Alan
AU - Backhausen, Lea L.
AU - Balachander, Srinivas
AU - Bargallo, Nuria
AU - Batistuzzo, Marcelo C.
AU - Benedetti, Francesco
AU - Bertolin Triquell, Sara
AU - Brem, Silvia
AU - Calesella, Federico
AU - Couto, Beatriz
AU - Denys, Damiaan A. J. P.
AU - Echevarria, Marco A. N.
AU - Eng, Goi Khia
AU - Ferreira, S. nia
AU - Feusner, Jamie D.
AU - Grazioplene, Rachael G.
AU - Gruner, Patricia
AU - Guo, Joyce Y.
AU - Hagen, Kristen
AU - Hansen, Bjarne
AU - Hirano, Yoshiyuki
AU - Hoexter, Marcelo Q.
AU - Jahanshad, Neda
AU - Jaspers-Fayer, Fern
AU - Kasprzak, Selina
AU - Kim, Minah
AU - Koch, Kathrin
AU - Bin Kwak, Yoo
AU - Kwon, Jun Soo
AU - Lazaro, Luisa
AU - Li, Chiang-Shan R.
AU - Lochner, Christine
AU - Marsh, Rachel
AU - Martínez-Zalacaín, Ignacio
AU - Menchon, Jose M.
AU - Moreira, Pedro S.
AU - Morgado, Pedro
AU - Nakagawa, Akiko
AU - Nakao, Tomohiro
AU - Narayanaswamy, Janardhanan C.
AU - Nurmi, Erika L.
AU - Zorrilla, Jose C. Pariente
AU - Piacentini, John
AU - Picó-Pérez, Maria
AU - Piras, Fabrizio
AU - Piras, Federica
AU - Pittenger, Christopher
AU - Reddy, Janardhan Y. C.
AU - Rodriguez-Manrique, Daniela
AU - Sakai, Yuki
AU - Shimizu, Eiji
AU - Shivakumar, Venkataram
AU - Simpson, Blair H.
AU - Soriano-Mas, Carles
AU - Sousa, Nuno
AU - Spalletta, Gianfranco
AU - Stern, Emily R.
AU - Evelyn Stewart, S.
AU - Szeszko, Philip R.
AU - Tang, Jinsong
AU - Thomopoulos, Sophia I.
AU - Thorsen, Anders L.
AU - Tokiko, Yoshida
AU - Tomiyama, Hirofumi
AU - Vai, Benedetta
AU - Veer, Ilya M.
AU - Venkatasubramanian, Ganesan
AU - Vetter, Nora C.
AU - Vriend, Chris
AU - Walitza, Susanne
AU - Waller, Lea
AU - Wang, Zhen
AU - Watanabe, Anri
AU - Wolff, Nicole
AU - Yun, Je-Yeon
AU - Zhao, Qing
AU - van Leeuwen, Wieke A.
AU - van Marle, Hein J. F.
AU - van de Mortel, Laurens A.
AU - van der Straten, Anouk
AU - van der Werf, Ysbrand D.
AU - Bin Kwak, Yoo
AU - Pariente Zorrilla, Jose C.
AU - Stewart, S. Evelyn
AU - van Leeuwen, Wieke A.
AU - van Marle, Hein J. F.
AU - van de Mortel, Laurens A.
AU - van der Straten, Anouk
AU - van der Werf, Ysbrand D.
AU - van den Heuvel, Odile A.
AU - van Wingen, Guido A.
AU - Thompson, Paul M.
AU - ENIGMA-OCD Working Group
AU - Stein, Dan J.
AU - van den Heuvel, Odile A.
AU - van Wingen, Guido A.
N1 - Funding Information: AA consults and holds equity with Neumora Therapeutics (formerly BlackThorn Therapeutics) and Manifest Technologies. AA also serves on the technology advisory board of Neumora Therapeutics and on the board of directors for Manifest Technologies. AA is a co-inventor on the following patents: AA, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019 and Murray JD, AA, Martin, WJ: Methods and tools for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject, U.S. Application No.16/149, filed on October 2, 2018, U.S. Application for PCT International Application No.18/054, 009 filed on October 2, 2018. JDF received consultant fees from NOCD, Inc. PM has received in the past 3 years grants, CME-related honoraria, or consulting fees from Angelini, AstraZeneca, Bial Foundation, Biogen, DGS-Portugal, FCT, FLAD, Janssen-Cilag, Gulbenkian Foundation, Lundbeck, Springer Healthcare, Tecnimede and 2CA-Braga. ELN disclosed that she is an unpaid advisory board member of Tourette Association of America and Myriad Genetics. In the last three years, BHS has received royalties from UpToDate, Inc, and Cambridge University Press and a stipend from the American Medical Association for serving as Associate Editor of JAMA-Psychiatry. PMT received unrelated research grant support from Biogen, Inc. All other individually-named authors in- and outside of the ENIGMA-OCD working group reported no biomedical financial interests or potential conflicts of interest. Funding Information: The ENIGMA-Obsessive Compulsive Disorder Working-Group gratefully acknowledges support from the Amsterdam Neuroscience (CIA-2019-03-A to OAvdH, Amsterdam Neuroscience Alliance Project to GAvW), and the NIH Big Data to Knowledge (BD2K) award for foundational support and consortium development (U54 EB020403 to PMT). For a complete list of ENIGMA-related grant support please see here: http://enigma.ini.usc.edu/about-2/funding/ . Additional funding was supported by the Japan Society for the Promotion of Science (JSPS; KAKENHI Grant No. 18K15523 to YA, Grant No. 22H01090, 21K03084, 19K03309, 16K04344 to YH, Grant No. (C)21K07547, 22K07598 and 22K15766 to TN and HT); the Carlos III Health Institute (Grant No. PI18/00856 to PA, Grant No. CM21/00278 (co-funded by the European Social Fund) to SBT, Grant No. FI17/00294 to IM-Z, Grant No. PI19/01171 to CS-M); the National Institute of Mental Health (NIMH; Grant No. 5R01MH116038 to AA, Grant No. R01MH085900 and R01MH121520 to JDF, Grant No. R01MH117601, R01AG059874, P41EB015922, R01MH126213 and R01MH121246 to NJ, Grant No. K23 MH115206 to PG, Grant No. R21MH101441 to RM, Grant No. R21MH093889 and R01MH104648 to RM and BHS, Grant No. R01MH085900 to JO’N, Grant. No. R01MH081864 to JO’N and JP, Grant No. K24MH121571 to CP, Grant No. R01MH126981, R01MH111794 and R33MH107589 to ERS, Grant No. R01MH116147, P41EB015922, and R01MH123163 to PMT); the Hartmann Müller Foundation (Grant No. 1460 to SB); the International Obsessive-Compulsive Disorder Foundation (IOCDF) Research Award to PG; the Japan Agency for Medical Research and Development (AMED Brain/MINDS Beyond program Grant No. JP22dm0307002 to YH and Grant No. JP22dm0307008 to YS); Michael Smith Foundation for Health Research to FJ-F; the Deutsche Forschungsgemeinschaft (DFG; Grant No. KO 3744/11-1 to KK, Grant NO. VE 892/2-1 to NCV and LLB); the Heidehof Stiftung to NCV; the Marató TV3 Foundation (Grant No. 091810 to LL); the Fondo de Investigaciones Sanitarias, of the Spanish Ministry of Health (Grant No. PI11/01419 to LL); the National Research Foundation of South Africa to CL; the South African Medical Research Council (SAMRC) to DJS and CL; the Portuguese Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia; FCT; Grant No. 2020.07946.BD to NS, Grant No. UIDB/50026/2020 and UIDP/50026/2020 to PM); the Norte Portugal Regional Operational Programme (NORTE 2020; Grant No. NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023 to PM and NS), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); the FLAD Science Award Mental Health 2021 to PM and NS; the Government of India grants from the Department of Science and Technology (Grants No. SR/S0/HS/0016/2011 to YCJR, and DST INSPIRE faculty Grant No. IFA12-LSBM-26 to JCN) and from the Department of Biotechnology (Grant No. BT/ PR13334/Med/30/259/2009 to YCJR, and Grant No. BT/06/IYBA/2012 to JCN); the Spanish Ministry of Universities with funds from the European Union—NextGenerationEU (Grant No. MAZ/2021/11 to MP-P); the National Council for Scientific and Technological Development (CNPq, Grant No. 303754/2018-4 to RGS); the Italian Ministry of Health (IRCCS Fondazione Santa Lucia Ricerca Corrente 2022, 2023 to FP, Grant No. RC19-20-21-22/A to GS); the Wellcome Trust-DBT India Alliance Senior Fellowship (Grant No. 500236/Z/11/Z to GV), Early Career Fellowship (Grant No. IA/CPHE/18/1/503956 to VS) and Clinical and Public Health Research Center grants (Grant No. IA/CRC/19/1/610005 to GV); the Catalan Agency for the Management of University and Research Grants (AUGUR Grant No. 2017SGR 1247 to CS-M); the National Natural Science Foundation of China (Grant No. 81871057 and 82171495 to JT, Grant No. 82071518 to ZW), and Key Technologies Research and Development Program of China (Grant No. 2022YFE0103700 to JT); the Obsessive-Compulsive Foundation to DJS; the Helse Vest Health Authority (Grant No. 911754 and 911880 to ALT); the Else-Kröner-Fresenius Foundation (Grant No. 2017_A101 to NW); the Swiss National Science Foundation (Grant No. 320030_130237 to SW); Netherlands Organization for Scientific Research (NWO/ZonMW Vidi Grant No. 165.610.002, 016.156.318, and 917.15.318 to GAvW, Grant No. 916.86.038 to OAvdH); The Brain & Behavior Research Foundation (NARSAD grant) and Netherlands Brain Foundation (Grant No. 2010(1)−(50)) to OAvdH and the National Institute on Aging Research Project Grant Program (Grant No. R01AG058854 to YDvdW) and the ENIGMA Parkinson’s Initiative: A Global Initiative for Parkinson’s Disease, NINDS award RO1NS107513 to YDvdW. Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Current knowledge about functional connectivity in obsessive-compulsive disorder (OCD) is based on small-scale studies, limiting the generalizability of results. Moreover, the majority of studies have focused only on predefined regions or functional networks rather than connectivity throughout the entire brain. Here, we investigated differences in resting-state functional connectivity between OCD patients and healthy controls (HC) using mega-analysis of data from 1024 OCD patients and 1028 HC from 28 independent samples of the ENIGMA-OCD consortium. We assessed group differences in whole-brain functional connectivity at both the regional and network level, and investigated whether functional connectivity could serve as biomarker to identify patient status at the individual level using machine learning analysis. The mega-analyses revealed widespread abnormalities in functional connectivity in OCD, with global hypo-connectivity (Cohen’s d: -0.27 to -0.13) and few hyper-connections, mainly with the thalamus (Cohen’s d: 0.19 to 0.22). Most hypo-connections were located within the sensorimotor network and no fronto-striatal abnormalities were found. Overall, classification performances were poor, with area-under-the-receiver-operating-characteristic curve (AUC) scores ranging between 0.567 and 0.673, with better classification for medicated (AUC = 0.702) than unmedicated (AUC = 0.608) patients versus healthy controls. These findings provide partial support for existing pathophysiological models of OCD and highlight the important role of the sensorimotor network in OCD. However, resting-state connectivity does not so far provide an accurate biomarker for identifying patients at the individual level.
AB - Current knowledge about functional connectivity in obsessive-compulsive disorder (OCD) is based on small-scale studies, limiting the generalizability of results. Moreover, the majority of studies have focused only on predefined regions or functional networks rather than connectivity throughout the entire brain. Here, we investigated differences in resting-state functional connectivity between OCD patients and healthy controls (HC) using mega-analysis of data from 1024 OCD patients and 1028 HC from 28 independent samples of the ENIGMA-OCD consortium. We assessed group differences in whole-brain functional connectivity at both the regional and network level, and investigated whether functional connectivity could serve as biomarker to identify patient status at the individual level using machine learning analysis. The mega-analyses revealed widespread abnormalities in functional connectivity in OCD, with global hypo-connectivity (Cohen’s d: -0.27 to -0.13) and few hyper-connections, mainly with the thalamus (Cohen’s d: 0.19 to 0.22). Most hypo-connections were located within the sensorimotor network and no fronto-striatal abnormalities were found. Overall, classification performances were poor, with area-under-the-receiver-operating-characteristic curve (AUC) scores ranging between 0.567 and 0.673, with better classification for medicated (AUC = 0.702) than unmedicated (AUC = 0.608) patients versus healthy controls. These findings provide partial support for existing pathophysiological models of OCD and highlight the important role of the sensorimotor network in OCD. However, resting-state connectivity does not so far provide an accurate biomarker for identifying patients at the individual level.
UR - http://www.scopus.com/inward/record.url?scp=85156271143&partnerID=8YFLogxK
U2 - 10.1038/s41380-023-02077-0
DO - 10.1038/s41380-023-02077-0
M3 - Article
C2 - 37131072
SN - 1359-4184
JO - Molecular Psychiatry
JF - Molecular Psychiatry
ER -